ArticlePLoS neglected tropical diseases2012
Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India.
Article in PLoS neglected tropical diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.PLoS neglected tropical diseases · 2014Trial
- Article
- Article
- In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani.BMC bioinformatics · 2022Article
- Mathematical modelling of the use of insecticide-treated nets for elimination of visceral leishmaniasis in Bihar, India.Royal Society open science · 2021Article
- Ascorbate peroxidase overexpression protects Leishmania braziliensis against trivalent antimony effects.Memorias do Instituto Oswaldo Cruz · 2018Article
- The role of case proximity in transmission of visceral leishmaniasis in a highly endemic village in Bangladesh.PLoS neglected tropical diseases · 2018Article
- Challenges in modeling complexity of neglected tropical diseases: a review of dynamics of visceral leishmaniasis in resource limited settings.Emerging themes in epidemiology · 2017Review
- Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis.Frontiers in immunology · 2017Review
- Optimal combinations of control strategies and cost-effective analysis for visceral leishmaniasis disease transmission.PloS one · 2017Article
- Magnesium-Dependent Ecto-ATP Diphosphohydrolase Activity in Leishmania donovani.Current microbiology · 2016Article
- Visceral Leishmaniasis on the Indian Subcontinent: Modelling the Dynamic Relationship between Vector Control Schemes and Vector Life Cycles.PLoS neglected tropical diseases · 2016Article
- Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature Review.PLoS neglected tropical diseases · 2016Review
- Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.Infectious diseases of poverty · 2016Review
- Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.PloS one · 2015Article
- Leishmania infantum ecto-nucleoside triphosphate diphosphohydrolase-2 is an apyrase involved in macrophage infection and expressed in infected dogs.PLoS neglected tropical diseases · 2014Article
- The new pyrazolyltetrazole derivative MSN20 is effective via oral delivery against cutaneous leishmaniasis.Antimicrobial agents and chemotherapy · 2014Article
- Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.PLoS neglected tropical diseases · 2014Article
- Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent.PLoS neglected tropical diseases · 2014Article
- Chronic arsenic exposure and microbial drug resistance.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPentavalent antimonials have been the mainstay of antileishmanial therapy for decades, but increasing failure rates under antimonial treatment have challenged further use of these drugs in the Indian subcontinent. Experimental evidence has suggested that parasites which are resistant against antimonials have superior survival skills than sensitive ones even in the absence of antimonial treatment. METHODS AND
findingsWe use simulation studies based on a mathematical L. donovani transmission model to identify parameters which can explain why treatment failure rates under antimonial treatment increased up to 65% in Bihar between 1980 and 1997. Model analyses suggest that resistance to treatment alone cannot explain the observed treatment failure rates. We explore two hypotheses referring to an increased fitness of antimony-resistant parasites: the additional fitness is (i) disease-related, by causing more clinical cases (higher pathogenicity) or more severe disease (higher virulence), or (ii) is transmission-related, by increasing the transmissibility from sand flies to humans or vice versa.
conclusionsBoth hypotheses can potentially explain the Bihar observations. However, increased transmissibility as an explanation appears more plausible because it can occur in the background of asymptomatically transmitted infection whereas disease-related factors would most probably be observable. Irrespective of the cause of fitness, parasites with a higher fitness will finally replace sensitive parasites, even if antimonials are replaced by another drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.